"instanceType","description","uuid:ID","name","id","label","rationale"
"StudyDesign","The main design for the study","78acf3e5-f446-4e18-897b-9cb873147450","Study Design 1","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
